MS patients suffer side-effects after NHS England switches to cheaper drug | Multiple sclerosis
Dozens of people with multiple sclerosis (MS) suffered NHS Driving to save money.
About 170 patients with Chris Cross patients in London, including the relapse of their disease, are suffering after they turned from Tispari to a different drug called Tyruko, by the Sandoz pharmaceutical company.
In a few cases, people with serious symptoms have been developed to the extent that they should be transferred to the hospital for treatment. Patients told doctors about side effects, including the inability to use their legs, other mobility problems, fatigue, pain and sudden weight gain.
It is not clear how long negative reactions are spread on Tyruko. NHS England said the problem was only seen at London Hospital. However, one of the patients there claimed that they knew people with multiple sclerosis in 15 other hospitals in England who have suffered similar setbacks to their health after they moved to Tyruko after sometimes taking TYSABRI.
Problems have arisen since NHS England began to transfer patients all over the country through a very active MS from Tysabri to Tyruko, which is “Biosimiar”, last April. BIOSIMIRAR is a copy of a drug that fell out of patents, allowing other drug companies to make a safe and effective legal drug like the original but on average is 72 % cheaper.
NHS England hopes to save one billion pounds over the next five years by expanding their use of drugs out of treatment for a set of conditions, including MS. It spends 17 billion pounds annually on medicines.
The side effects of Tyruko caused a lot of anxiety in the health service that NHS England is in discussion with the Ministry of Health and Social Welfare (DHSC) and the Drug Administration and Healthcare Products (MHRA) about what to do.
The result will be eagerly awaiting patients with multiple sclerosis and charitable societies as well as specialists in the disease. About half of the NHS hospital network that treats people with multiple sclerosis are already involved in the NHS England show of converting those on Tysabri into Tyruko instead.
“The safety of patients is our first priority. We seek to understand the situation in Impierial NHS TRUST, which seems to contradict the experience of patients in other UK hospitals. We believe it is too early to extract conclusions at this stage. We continue to work with NHS And the organizational authorities to solve this.
They added that “Tysabri and Tyruko are considered to be switched by MHRA, which has determined that there are no significant differences between the two versions.”
Before starting the switch, Imperial College Healthcare NHS TRUST, which runs Chars Cross, had 345 patients on Tysabri – the largest number in the United Kingdom. Tyruko began to give them instead last May. Doctors are expected to see some moderate side effects in the short term as a result of the switch, as happened with the introduction of previous Biosimilars.
But about half of their patients reported “the ongoing and important side effects that have worsened for a few months, which was not expected.” All of them are now run to Tysabri.
In a letter he sent to patients with multiple sclerosis in December, Imperial said: “Doctors expected that some patients report the side effects but only relatively mild that were resolved after a short period.
“However, a number of our patients have reported a constant exacerbation of their side effects and/or symptoms of multiple sclerosis after turning into Thiroco.” All of them were reviewed by a doctor or a master’s nurse in multiple nervous sclerosis.
“There should be an investigation into the reason for seeing these side effects, and whether they are to people who return to the formula with brands,” said drug expert, Dr. Andrew Hill, a research colleague at the Pharmacy Department at the University of Liverpool.
He added that any investigation should be seen whether the negative reactions to Tiroko were seen in other countries.
A NHS spokesman said: “We understand that important side effects reports have focused on the patient’s experience in one confidence,” a NHS spokesman said.
“We are currently in discussions with MHRA and the Ministry of Health and Social Welfare to determine what MS centers can take throughout the country, if any, throughout the country after the reported experiences of patients under the auspices of the imperial health care confidence.”
MS groups said they were aware of negative reactions, but they suggested that only small numbers of patients be affected.
“We are aware of a handful of people who have suffered from great symptoms after switching,” said the multiple sclerosis box. But the fact that patients concerned have a very active multi -sclerosis “means that multiple sclerosis may be difficult to manage, and the new symptoms may be a common element in their diagnosis.”
“Some people have told our MS aid line that they have started experimenting with side effects since the shift from Tysabri to Tyruko, and some told us that they are not sure if Tyruko was effective. However, there are many others who They have not reported any problems at all.
